ArticleMedicine2026
Bibliometric analysis and visualization of adenomyosis: From 1980-2024.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThis bibliometric analysis systematically evaluated the research landscape, emerging trends, and key focus areas in adenomyosis to guide future research directions.
designPerformance analysis combined with scientific mapping of global adenomyosis research literature. DATA SOURCES: Web of Science Core Collection (1980-2024). DATA EXTRACTION AND SYNTHESIS: Articles were manually screened. Bibliometrix (R 4.3.0), VOSviewer, and CiteSpace analyzed productivity, collaboration, citation patterns, and research trends. Derived data and analysis scripts are deposited in the Open Science Framework (OSF) under a citable DOI.
resultsAmong 3100 included publications, China led output (752, 24.26%, full-counted), followed by the United States (414, 13.35%), Japan (350, 11.29%), Italy (215, 6.94%), and South Korea (128, 4.13%). In the 2 adenomyosis-specific corpora, however, the United States ranked first. The US had the highest citations and international collaboration, though international co-authorship among top-producing countries remained low (16.14%). Leading institutions were Fudan University (89), Shandong University (52), and University of Tokyo (49). Top journals by volume: Fertility and Sterility, Human Reproduction, and Journal of Minimally Invasive Gynecology. Research focus shifted from hysterectomy and uterine artery embolization toward high-intensity focused ultrasound (HIFU), and from endothelial nitric oxide synthase/induced adenomyosis toward ectopic endometrium. Eight keyword clusters emerged; the 4 largest (#0 EMT, #1 HIFU, #2 endometrial cancer, #3 pregnancy outcomes) form the present focus. Burst analysis identified "consensus" (2020-2024), "pathogenesis" (2022-2024), and "pregnancy outcome" (2022-2024) as recent and currently active hotspots.
conclusionsCurrent adenomyosis research centers on ectopic endometrium and EMT in pathogenesis, fertility outcomes, long-term efficacy of HIFU and fertility-sparing surgery, links to endometrial cancer, and adverse pregnancy outcomes. Beyond deepening pathogenesis and pregnancy-outcome research, key future directions include enhancing international collaboration and developing internationally agreed, evidence-based standardized terminology, diagnostic criteria, and classification systems for adenomyosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.